Fingolimod suppresses bone resorption in female patients with multiple sclerosis - Miyazaki, Yusei; Niino, Masaaki; Kanazawa, Ippei; Suzuki, Masako; Mizuno, Masanori; Hisahara, Shin; Fukazawa, Toshiyuki; Takahashi, Eri; Amino, Itaru; Ochi, Ryutaro; Nakamura, Masakazu; Akimoto, Sachiko; et al. (Journal of neuroimmunology, 2016)
Keywords: Adult; Allergy and Immunology; Bone resorption; Bone Resorption - drug therapy; Bone Resorption - etiology; Collagen Type I - urine; Disability Evaluation; Female; Fingolimod; Fingolimod Hydrochloride - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - complications; Multiple Sclerosis - drug therapy; Multiple Sclerosis - urine; Neurology; Osteoclasts; Osteoporosis; Peptide Fragments - metabolism; Peptides - urine; Procollagen - metabolism; Sex Characteristics; Sphingosine-1-phosphate; Tartrate-Resistant Acid Phosphatase - metabolism; RANKL; Multiple sclerosis; Fingolimod; MS; S1PR; P1NP; uNTX; ECLIA; IFN; Bone resorption; BAP; Osteoporosis; S1P; TRACP; Sphingosine-1-phosphate; Osteoclasts; HC; EIA; UT; BMI; EDSS; sphingosine-1-phosphate receptor; electro-chemiluminescence immunoassay; expanded disability status scale; bone-specific alkaline phosphatase; receptor activator of nuclear factor kappa-B ligand; healthy controls; untreated; multiple sclerosis; body mass index; tartrate-resistant acid phosphatase; interferon; enzyme immunoassay; urinary type I collagen cross-linked N-telopeptide; procollagen type 1 amino-terminal propeptide; sphingosine-1-phosphate